Contract research organisation hVIVO plc (AIM:HVO) announced on Monday that it has signed an agreement with clinical-stage biotechnology company Inhalon Biopharma Inc to conduct a Respiratory Syncytial Virus (RSV) human challenge trial.
The Phase 2a trial will assess Inhalon's inhaled antiviral candidate, IN-002, using hVIVO's RSV Human Challenge Model. It will evaluate IN-002's safety, pharmacokinetics and antiviral activity at three dose levels.
hVIVO's FluCamp will recruit healthy volunteers for the study. The trial is expected to begin in the second half of 2026 at hVIVO's Canary Wharf facilities.
Revenue from the contract is primarily expected to be recognised in 2026.
IN-002 uses Inhalon's inhaled drug delivery platform.
ContextVision partners with University of Washington to advance liver disease diagnostics
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
hVIVO to conduct RSV human challenge trial for Inhalon Biopharma
Moberg Pharma and Allderma announce launch of Terclara in Norway
CHMP recommends EU approval of Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan
Sanofi secures China approval for Sarclisa in newly diagnosed multiple myeloma
Renalys Pharma completes patient enrolment for Phase III clinical trial of sparsentan
H. Lundbeck A/S reports positive results from open-label extension of Phase 1b/2a bexicaserin trial
Invenra and Orion partner to develop bispecific antibody cancer therapies
Novo Nordisk Foundation awards record DKK10.1bn for health and sustainability initiatives
Amgen's BLINCYTO (blinatumomab) monotherapy approved in Europe
ImmunityBio partners with BeiGene for Phase 3 NSCLC trial of ANKTIVA and PD-1 inhibitor